

CONTENTS

Thomas M. Dunlap <i>Managing Partner, DunlapWeaver PLLC</i> THE BRAVE NEW WORLD: OWNING AND PROTECTING BIOTECHNOLOGY IDEAS, INVENTIONS, AND IP IN A POST ALA WORLD	7
Cara Baer <i>Partner, Butler Snow LLP</i> UNCERTAINTY IN BIOPHARMACEUTICAL INDUSTRY PRESENTS CHALLENGES FOR MANUFACTURERS	25
Alan E. Schiavelli <i>Managing Partner, Antonelli Terry Stout & Kraus LLC</i> INTER PARTES REVIEW CLOSING THE GAP BETWEEN BIOTECH 510(K) AND 505(B)(2) APPLICATIONS: FDA-GRANTED MONOPOLIES FOR PATENT EXCLUSIVITY	37
Susan J. Mack <i>Principal, Sughrue Mion PLLC</i> NEW POLITICAL AND REGULATORY ISSUES COMPLICATE PROTECTING BIOTECHNOLOGY INTELLECTUAL PROPERTY	53
Brett Godfrey <i>Founding Partner, Godfrey Johnson PC</i> LAW MUST KEEP PACE WITH INCREASINGLY SOPHISTICATED TECHNOLOGY TO PROTECT THE PUBLIC HEALTH	71

Martha E. Marrapese and Leslie T. Krasny <i>Partners, Keller and Heckman LLP</i> <i>ADDRESSING THE COMPLEXITIES OF REGULATORY SCHEMES FOR GMOS AND PRODUCTS DERIVED FROM THEM</i>	93
Peter I. Bernstein <i>Partner, Scully Scott Murphy & Presser PC</i> <i>BIOTECH PATENTS ENTER UNCHARTED WATERS FOLLOWING RECENT COURT DECISIONS</i>	139
James M. Francis <i>Member, Francis Law PLLC</i> <i>PATENT REFORM'S UNINTENDED CONSEQUENCES IN BIOTECH</i>	151
Appendices	161

APPENDICES

Appendix A: Guidance For Industry: New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products	162
Appendix B: Guidance For Industry: Applications Covered by Section 505(b)(2)	173
Appendix C: Memorandum: PTO Guidance	186
Appendix D: 133 S.Ct. 2107	219
Appendix E: 132 S.Ct. 1289	243
Appendix F: 134 S.Ct. 2111	273
Appendix G: 133 S.Ct. 1761	294
Appendix H: Memorandum: <i>Association for Molecular Pathology v. Myriad Genetics, Inc.</i>	309